Antiestrogens: Mechanism of action and clinical applications;Antiestrógenos: Mecanismo de accíon y aplicaciones clínicas

Salud Publica de Mexico

Volumn 43, Issue 6, 2001, Pages 577-584

  Barrón González, Arturo ^a   Arias Martínez, Joel ^a   Castro Romero, Ivone ^a,b  

^a SECRETARÍA DE SALUD   (Mexico)

^b INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

Author keywords

Breast neoplasms; Estrogen antagonists; Estrogens; Selective estrogen receptor modulators

Indexed keywords

ANTIESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RISK; DRUG MECHANISM; ESTROGEN ACTIVITY; HUMAN; REVIEW; RISK FACTOR; TARGET CELL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; POSTMENOPAUSE; RALOXIFENE; RISK FACTORS; TAMOXIFEN; TOREMIFENE;

EID: 0035686334     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Estrogens as a cause of human cancer: The Richard and Linda Rosenthal Foundation award lecture
2. Estrogens and breast cancer
3. Selective estrogen receptor modulators: A new paradigm for HRT
4. Selective modulation of estrogen receptor action
5. Selective estrogen receptor modulators: Women's panacea for next millennium
6. Immunohistochemical localization of estrogen receptor in rat brain, pituitary and uterus with monoclonal antibodies
7. Estrogen regulates the expression of several different estrogen receptor mRNA isoforms in rat pituitary
8. The endometrium: Regulation and dysfunction
9. Proliferation and secretory activity in human breast during natural and artificial menstrual cycles
10. Actions of ovarian steroid hormones
11. The hypotalamus and pituitary gland
12. Estrogen receptors in non-target tissues: Biological and clinical implications
13. El receptor de estrógenos y la glándula mamaria
14. Sequence and expression of human estrogen receptor complementary DNA
15. ERβ: Identification and characterization of a novel human estrogen receptor
16. Human estrogen receptor b gene structure, chromosomal localization and expression pattern
17. The complete primary structure of human estrogen receptor b and his heterodimerization with ERa in vivo and in vitro
18. Cloning and characterization of human estrogen receptor β isoformas
19. An update on estrogen receptors
20. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH technique
21. Oestrogen receptors - An overview
22. Mouse estrogen receptor b forms estrogen response element-binding heterodimers with estrogen receptor a
23. The estrogen receptor b isoform (ERb) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
24. Structure and function of the estrogen receptor
25. Structure and function of estrogen receptors
26. Genetic and epigenetic alterations of the estrogen receptor gene and hormone independence in human breast cancer
27. A monohydroxylated metabolite of tamoxifen with potent anti-oestrogenic activity
28. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
29. Antiestrogens: Mechanism and actions in target cells
30. Different regions in activation function-I of the human estrogen receptor required for antiestrogen-and estradiol-dependent transcription activation
31. Identification of a third autonomous activation domain within the human estrogen receptor
32. A new interpretation of estrogen action
33. Coactivator peptides have a differential stabilising effect on the binding of estrogens and antiestrogens with the estrogen receptor
34. An estrogen receptor-selective corregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens
35. Tamoxifen resistant breast cancer: Corregulators determine the direction of transcription by antagonist-occupied steroid receptors
36. Differential response of estrogen receptor b to partial estrogen agonists/antagonists
37. Differential ligand activation of estrogen receptors a and b at AP I sites
38. Basic guides to the mechanism of antiestrogen action
39. Systematic Treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 Randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
40. Tamoxifen for early breast cancer: An overview of the randomized trials
41. Should adjuvant tamoxifen treatment be stopped at 5 years?
42. Review of pharmacological properties of Toremifene
43. Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in Female Crl: CD (BR) rats
44. Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens
45. Comparison between the effects of tamoxifen and toremifen on the uterus in postmenopausal breast cancer patients
46. Metabolism of the 4-yodo derivative of tamoxifen by isolated rat hepatocytes: Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites
47. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer
48. Preclinical data for Droloxifene
49. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
50. Clinical potential of new antiestrogens
51. Uterine bioassays of tamoxifen, trioxifen and a new estrogen antagonist (LY 117018) in rats and mice
52. Evidence for biological action of the antiestrogens LY 117018 and tamoxifen by different mechanisms
53. Antagonism of estrogen action with a new benzothiophene-derived antiestrogen
54. Inhibition of the uterotrophic activity of estrogens and antiestrogens by the short acting antiestrogens LY117018
55. Effects of antiestrogens on bone in castrated and in intact female rats
56. Advantages of raloxifen over alendronato or estrogen on non-reproductive tissues in the-long term dosing of ovariectomized rats
57. Raloxifene inhibits bone turnover and prevents further cancerous bone loss in adult ovariectomized rats with stablisshed osteopenia
58. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene, tamoxifen, estrogen and alendronate
59. A controlled trial of raloxifene: Impact on bone turnover and serum lipid in healthy postmenopausal women
60. Antiestrogenic effects of LY 117018 in MCF-7 cells
61. The antitumor action of keoxifene and tamoxifen in the N-nitrosomethyurea-induced rat mammary carcinoma model
62. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifen and 9-cis-retinoic acid
63. Selective estrogen receptor modulators
64. Phase II evaluation of LY156758 in metastatic breast cancer
65. Inhibition of estrogen receptor-DNA binding by the pure antiestrogen ICI 164 384 appears to be mediated by impaired receptor dimerization
66. The mechanism of ICI 164 384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
67. The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasming shuttling
68. Inhibition of tamoxifen stimulated growth of MCF-7 tumour variants in athymic mice by novel steroidal antiestrogens
69. A potent specific pure antiestrogen with clinical potential
70. Effect of steroidal and non-steoidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCal01) in athymic mice
71. Antiuterotrophic effect of the pure antiestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): Quantitative magnetic resonance imaging
72. Investigation of a pure new antiestrogen (ICI 182,780) in women with primary breast cancer
73. Novel antiestrogens without partial agonist activity
74. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a-model of human cancer
75. ICI 182 780 (Faxiode™). Development of a novel, "pure" antiestrogen
76. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk
77. Serum sex hormones levels after menopause and subsequent breast cancer
78. Tetosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expresion